Table 2.
Three-year clinical outcome of patients with normoglycemia, prediabetes or diabetes
| Normo-glycemia n=2353 |
Prediabetes n=489 |
Diabetes n=1488 |
Prediabetes vs. Normoglycemia | Diabetes vs. Normoglycemia | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | Adjusted | Unadjusted | Adjusted | ||||||||
|
HR (95 % CI) |
p-value | HR (95 %CI) | p-value |
HR (95 % CI) |
p-value |
HR (95 % CI) |
p-value | ||||
| Target vessel failure | 142 (6.1) | 54 (11.2) | 197 (13.7) | 1.89 (1.38–2.58) | < 0.001 | 1.79 (1.31–2.45) | < 0.001 | 2.30 (1.85–2.86) | < 0.001 | 2.03 (1.63–2.52) | < 0.001 |
| Any death | 80 (3.4) | 26 (5.4) | 112 (7.7) | 1.59 (1.02–2.47) | 0.04 | 1.54 (0.99–2.40) | 0.06 | 2.3 (1.72–3.05) | < 0.001 | 2.11 (1.58–2.82) | < 0.001 |
| Cardiac death | 26 (1.1) | 15 (3.1) | 49 (3.4) | 2.81 (1.49–5.30) | 0.001 | 2.70 (1.43–5.10) | 0.002 | 3.1 (1.91–4.94) | < 0.001 | 2.76 (1.71–4.45) | < 0.001 |
| Any MI | 72 (3.1) | 23 (4.8) | 87 (6.1) | 1.56 (0.98–2.49) | 0.06 | 1.49 (0.93–2.38) | 0.10 | 2.0 (1.45–2.70) | < 0.001 | 1.77 (1.29–2.42) | < 0.001 |
| Target vessel MI | 57 (2.5) | 17 (3.6) | 65 (4.5) | 1.45 (0.84–2.49) | 0.18 | 1.36 (0.79–2.33) | 0.27 | 1.84 (1.29–2.63) | 0.001 | 1.59 (1.11–2.28) | 0.011 |
| Any revascularization | 159 (6.9) | 55 (11.6) | 195 (13.8) | 1.72 (1.27–2.34) | 0.001 | 1.66 (1.22–2.25) | 0.001 | 2.07 (1.68–2.56) | < 0.001 | 1.88 (1.52–2.32) | < 0.001 |
| Target vessel revascularization | 85 (3.7) | 33 (7.0) | 118 (8.4) | 1.92 (1.29–2.87) | 0.001 | 1.81 (1.21–2.71) | 0.004 | 2.31 (1.75–3.06) | < 0.001 | 2.05 (1.55–2.71) | < 0.001 |
| Target lesion revascularization | 49 (2.1) | 26 (5.5) | 78 (5.5) | 2.62 (1.63–4.22) | < 0.001 | 2.48 (1.54–4.00) | < 0.001 | 2.63 (1.84–3.76) | < 0.001 | 2.33 (1.62–3.34) | < 0.001 |
| Target lesion failure | 115 (5.0) | 49 (10.2) | 159 (11.0) | 2.11 (1.51–2.94) | < 0.001 | 2.01 (1.44–2.80) | < 0.001 | 2.28 (1.79–2.89) | < 0.001 | 2.00 (1.57–2.55) | < 0.001 |
| MACE | 179 (7.7) | 63 (13.0) | 235 (16.0) | 1.75 (1.31–2.33) | < 0.001 | 1.69 (1.27–2.25) | < 0.001 | 2.19 (1.80–2.66) | < 0.001 | 1.98 (1.62–2.40) | < 0.001 |
| Definite-or-probable stent thrombosis | 10 (0.4) | 5 (1.1) | 23 (1.6) | 2.43 (0.83–7.10) | 0.11 | 2.30 (0.79–6.75) | 0.13 | 3.73 (1.77–7.83) | 0.001 | 3.35 (1.58–7.09) | 0.002 |
| Definite stent thrombosis | 9 (0.4) | 2 (0.4) | 14 (1.0) | 1.08 (0.23–4.99) | 0.92 | 1.03 (0.22–4.78) | 0.97 | 2.52 (1.09–5.82) | 0.030 | 2.30 (0.99–5.37) | 0.053 |
| Bleeding | 96 (4.2) | 28 (5.9) | 93 (6.5) | 1.43 (0.94–2.18) | 0.09 | 1.32 (0.83–2.09) | 0.24 | 1.59 (1.19–2.11) | 0.001 | 1.19 (0.85–1.67) | 0.32 |
| Major Bleeding | 53 (2.3) | 19 (3.9) | 59 (4.1) | 1.76 (1.04–3.98) | 0.034 | 1.60 (0.89–2.91) | 0.12 | 1.81(1.25–2.63) | 0.002 | 1.35 (0.89–2.12) | 0.20 |
Values are n (%)
MI, myocardial infarction; MACE, major adverse cardiac events